Tags

Type your tag names separated by a space and hit enter

Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Eur J Med Chem. 2009 Nov; 44(11):4259-65.EJ

Abstract

Inhibitors of transforming growth factor-beta Type I Receptor (ALK5) have been thought as potential drugs for the treatment of fibrosis and cancer and a considerable number of ALK5 inhibitors have been reported recently. In order to clarify the essential structure-activity relationship for the known ALK5 inhibitors as well as identify new lead compounds against ALK5, 3D pharmacophore models have been established based on the known ALK5 inhibitors. The best pharmacophore model, Hypo1, was used as a 3D search query to perform a virtual screening. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits. Finally a total of 100 compounds were obtained and some of them were selected for further in vitro and in vivo assay studies.

Authors+Show Affiliations

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19640613

Citation

Ren, Ji-Xia, et al. "Pharmacophore Modeling and Virtual Screening for the Discovery of New Transforming Growth Factor-beta Type I Receptor (ALK5) Inhibitors." European Journal of Medicinal Chemistry, vol. 44, no. 11, 2009, pp. 4259-65.
Ren JX, Li LL, Zou J, et al. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. Eur J Med Chem. 2009;44(11):4259-65.
Ren, J. X., Li, L. L., Zou, J., Yang, L., Yang, J. L., & Yang, S. Y. (2009). Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. European Journal of Medicinal Chemistry, 44(11), 4259-65. https://doi.org/10.1016/j.ejmech.2009.07.008
Ren JX, et al. Pharmacophore Modeling and Virtual Screening for the Discovery of New Transforming Growth Factor-beta Type I Receptor (ALK5) Inhibitors. Eur J Med Chem. 2009;44(11):4259-65. PubMed PMID: 19640613.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. AU - Ren,Ji-Xia, AU - Li,Lin-Li, AU - Zou,Jun, AU - Yang,Li, AU - Yang,Jin-Liang, AU - Yang,Sheng-Yong, Y1 - 2009/07/16/ PY - 2008/12/03/received PY - 2009/05/18/revised PY - 2009/07/09/accepted PY - 2009/7/31/entrez PY - 2009/7/31/pubmed PY - 2010/1/29/medline SP - 4259 EP - 65 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 44 IS - 11 N2 - Inhibitors of transforming growth factor-beta Type I Receptor (ALK5) have been thought as potential drugs for the treatment of fibrosis and cancer and a considerable number of ALK5 inhibitors have been reported recently. In order to clarify the essential structure-activity relationship for the known ALK5 inhibitors as well as identify new lead compounds against ALK5, 3D pharmacophore models have been established based on the known ALK5 inhibitors. The best pharmacophore model, Hypo1, was used as a 3D search query to perform a virtual screening. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits. Finally a total of 100 compounds were obtained and some of them were selected for further in vitro and in vivo assay studies. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/19640613/Pharmacophore_modeling_and_virtual_screening_for_the_discovery_of_new_transforming_growth_factor_beta_type_I_receptor__ALK5__inhibitors_ DB - PRIME DP - Unbound Medicine ER -